Personalized medicine: are payers the weak link?

Bibliography

• 1  Deverka P, Vernon J, McLeod H: Economic opportunities and challenges for pharmacogenomics. Annu. Rev. Pharmacol. Toxicol.50,423–437 (2010).
  Medline CASGoogle Scholar
• 2  Gold H, Hall M, Blinder V et al.: Cost–effectiveness of pharmacogenomics testing for UGT1A1 before irinotecan administration for metastatic colorectal cancer. Cancer115(17),3858–3867 (2009).
  Medline CASGoogle Scholar
• 3  Deverka P: Pharmacogenomics, evidence, and the role of payers. Pub. Health Genomics12,149–157 (2009).
  Medline CASGoogle Scholar
• 4  Piccart-Gebhart M, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N. Engl. J. Med.352,1659–1672 (2005).
  Google Scholar
• 5  Romond E, Perez E, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N. Engl. J. Med.353,1673–1684 (2005).
  Medline CASGoogle Scholar
• 6  Frueh F, Amur S, Mummaneni M et al.: Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy28(8),992–998 (2008).
  MedlineGoogle Scholar
• 7  Lievre A, Bachet J, Le Corre D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res.66(8),3992–3995 (2006).
  Medline CASGoogle Scholar
• 8  Rogowski W, Grosse S, Khoury M: Challenges of translating genetic tests into clinical and public health practice. Nat. Rev. Genet.10,489–495 (2009).
  Medline CASGoogle Scholar
• 9  Khoury M, Berg A, Coates R et al.: The evidence dilemma in genomic medicine. Health Aff.27(6),1600–1611 (2008).
  MedlineGoogle Scholar
• 10  Phillips K, Van Bebber S: A systematic review of cost–effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics5,1139–1149 (2004).
  Google Scholar
• 11  Gerber AM, Tunis S: Does comparative-effectiveness research threaten personalized medicine?. N. Engl. J. Med.360,1925–1927 (2009).
  MedlineGoogle Scholar
• 12  Meckley L, Neumann P: Personalized medicine: factors influencing reimbursement. Health Pol.94,91–100 (2010).
  MedlineGoogle Scholar
• 13  Phillips K: The intersection of biotechnology and pharmacogenomics: health policy implications. Health Aff.25,1271–1280 (2006).
  Google Scholar
• 14  Paci D, Ibarreta D: Economic and cost–effectiveness considerations for pharmacogenetics tests: an integral part of translational research and innovation uptake in personalized medicine. Curr. Pharmacogen. Pers. Med.7,284–296 (2009).
  CASGoogle Scholar
• 15  Epstein R, Teagarden J: Comparative effectiveness research and personalized medicine. Pharmacoeconomics28(10),905–913 (2010).
  MedlineGoogle Scholar
• 16  Dendukuri N, Khetani K, McIsaac M et al.: Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ176(10),1429–1434 (2007).
  MedlineGoogle Scholar
• 17  Tanisha C, Reginald D, Williams A et al.: Medicare’s coverage of colorectal cancer drugs: a case study in evidence development and policy. Health Aff.25(5),1231–1239 (2009).
  Google Scholar
• 18  Hamburg M, Collins F: The path to personalized medicine. N. Engl. J. Med.363,301–304 (2010).
  Medline CASGoogle Scholar
• 19  Hallberg B, Palmer R: Crizotinib – latest champion in the cancer wars?. N. Engl. J. Med.363,1760–1762 (2010).
  Medline CASGoogle Scholar
• 20  Jenkins A: A dying wish. Forbes Mag.28 (2011).
  Google Scholar